Anti-diabetics


Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.

NameCAS number
Albiglutide782500-75-8
Buformin692-13-7
Canagliflozin842133-18-0
Chlorpropamide94-20-2
Dapagliflozin461432-26-8
Dapagliflozin Propanediol Monohydrate1187594-09-7
Dulaglutide923950-08-7
Empagliflozin864070-44-0
Ertugliflozin1210344-57-2
Exenatide141758-74-9
Fenugreek seed
Glibenclamide10238-21-8
Gliclazide21187-98-4
Glimepiride93479-97-1
Glipizide29094-61-9
Gliquidone33342-05-1
Glyburide10238-21-8
Insulin Aspart116094-23-6
Insulin Glargine160337-95-1
Insulin Human11061-68-0
Insulin Lispro133107-64-9
Linagliptin668270-12-0
Liraglutide204656-20-2
Lixisenatide320367-13-3
Metformin657-24-9
Pioglitazone111025-46-8
Saxagliptin361442-04-8
Semaglutide
Sitagliptin486460-32-6
Sitagliptin Phosphate654671-77-9
Thiazolidincarboxylic Acid
Tolazamide1156-19-0
Tolbutamide64-77-7
Troglitazone97322-87-7
Vildagliptin274901-16-5